Hillstream BioPharma, Inc.
HILS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $1 | $1 | $4 |
| G&A Expenses | $2 | $1 | $2 | $2 |
| SG&A Expenses | $2 | $1 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $2 | $3 | $6 |
| Operating Income | -$2 | -$2 | -$3 | -$6 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | -$2 | -$2 | -$3 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$3 | -$5 |
| % Margin | – | – | – | – |
| EPS | -0.34 | -0.64 | -1.96 | -4.14 |
| % Growth | 46.9% | 67.3% | 52.7% | – |
| EPS Diluted | -0.34 | -0.64 | -1.96 | -4.14 |
| Weighted Avg Shares Out | 6 | 3 | 1 | 1 |
| Weighted Avg Shares Out Dil | 6 | 3 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | -$0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$2 | -$2 | -$3 | -$5 |
| % Margin | – | – | – | – |